Intellect Neurosciences, Inc.

For biopharma patent owners, the impact of inter partes review (IPR) proceedings can be summed up in one word: uncertainty. They say this patent challenge process prevents them from knowing when they

Pfizer Inc. 's experience in defending its Tygacil (tygecycline) patent against an inter partes review challenge shows brand-name drug makers have a good shot at prevailing in these proceedings. Th

Agilis Biotherapeutics has entered into a deal with synthetic biology firm Intrexon to develop DNA-based therapeutics for the rare genetic disease, Friedreich's ataxia. New York-based Agilis and Germa

Intellect Neurosciences Inc. has filed a breach of contract suit against Pfizer Inc. for failing to make a $2 million milestone payment for rights to its Alzheimer’s disease technology. Intellec